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We study minimal mean-field models of viral drug resistance development in which the efficacy
of a therapy is described by a one-dimensional stochastic resetting process with mixed reflecting-
absorbing boundary conditions. We derive analytical expressions for the mean survival time for the
virus to develop complete resistance to the drug. We show that the optimal therapy resetting rates
that achieve a minimum and maximum mean survival times undergo a second and first-order phase
transition-like behaviour as a function of the therapy efficacy drift. We illustrate our results with
simulations of a population-dynamics model of HIV-1 infection.
Antiviral and antiretroviral therapies are continuously
being developed to tackle viral diseases [1]. Because of
viral evolution, a therapy that is effective today may not
remain effective forever [2]. This process is known as drug
resistance development and it is of special importance in
chronic infections such as HIV-1 [3–5], and also for herpes
and hepatitis [6]. Viral evolution results into an increase
in the number of infected cells, leading to a failure of the
normal functions of the infected patient that can result
in their death [2]. Because viruses replicate and mutate
rapidly, and mutation is a random process, viral evolu-
tion is intrinsically noisy [7, 8]. When possible, prac-
titioners overcome this situation by changing the ther-
apy given to the patient. Changes in antiviral therapies
can occur because of a detected viral resistance [3, 9],
or for purely stochastic reasons e.g. the appearance in
the market of a therapy that is cheaper or has less sec-
ondary effects. It remains an open yet challenging prob-
lem to characterize and design therapy change protocols
that ensure large patient survival times that are robust
to drug-resistance fluctuations.
Stochastic models have been used to study viral evo-
lution [7–11]. Examples include the usage of branching
process to describe viral persistence and extinction [7, 8],
and population dynamics models to assess the impact of a
treatment in drug resistance development in the context
of HIV-1 [12]. A model that described RNA virus evolu-
tion as a diffusion process in a fitness landscape [13] was
able to explain the experimentally-observed rapid initial
growth followed by a slower stage of linear growth in the
logarithm of fitness of clone colonies of vesicular stom-
atitis virus [14, 15]. In the same vein, the notion of a
fluctuating therapy efficacy can be used to describe the
evolution of therapy protocols.
Viral evolution can be modelled as a stochastic dif-
fusion process involving incremental changes in efficacy
—due to viral mutation— punctuated by sudden changes
in efficacy —due to changes in therapy—. Diffusions
FIG. 1. Illustration of the stochastic-resetting model of an-
tiviral therapy efficacy. Top: Sketch of the main ingredients
of the model. Bottom: Sample trajectory of the therapy ef-
ficacy as a function of time, with A-D illustrating key events
during a single realization of the process. A) Initial condi-
tion, for a 50% efficient therapy η0 = 1/2. B) Change of the
current therapy at a random time (stochastic resetting) by
a new one with 50% efficacy. C) Reflecting boundary condi-
tion modelling the maximum possible therapy efficacy η = 1.
D) Absorbing boundary condition yielding to the dead of the
patient due to a completely inefficient therapy η = 0.
with stochastic resetting [16–27] thus provide a promis-
ing framework to model therapy evolution. This frame-
work has been instrumental to describe biophysical pro-
cesses with sudden changes, namely RNA polymerase
backtracking [28, 29], receptor dynamics [30], cell crawl-
ing [31], and population dynamics [32–34], see [17] for a
review of applications. It remains unclear how in mul-
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2tiscale processes stochastic resetting of a slow variable
(e.g. a therapy efficacy) affects a fast variable describing
the dynamics of a time-varying population (e.g. cells and
viruses).
In this Letter, we introduce a stochastic-resetting
model for the evolution of the efficacy of an antiviral ther-
apy, and study its evolution under different treatment
protocols. We first describe the therapy efficacy as a one-
dimensional resetting biased diffusion model with mixed
absorbing and reflecting boundaries, calculate an exact
analytical expression for the mean first passage time, and
test our result by comparing it with Langevin dynamics
simulations. We then discuss the clinical effects of our vi-
ral evolution model by coupling the stochastic resetting
biased-diffusion therapy efficacy to a population dynam-
ics model of HIV-1 chronic disease.
We describe the efficacy of an antiviral treatment as a
bounded stochastic process 0 ≤ η(t) ≤ 1 where η = 0 and
η = 1 correspond to a completely ineffective and com-
pletely effective therapy, respectively. We assume that
treatments that stop working lead to the death of the
patient, i.e. η = 0 is an absorbing boundary. On the
other hand η = 1 is a reflecting boundary set at the
maximum 100% therapy efficacy. We model the evolu-
tion of therapy efficacy η(t) as a biased random walk or
drift-diffusion process in ”efficacy space” with diffusion
coefficient D and drift v. The therapy is often biased in
the direction of lesser efficacy, i.e. the drift is negative
v < 0, due to the fact that viruses develop resistance
to the existing therapies that survive in the long run.
Furthermore, we complement the biased diffusion model
with a resetting protocol that switches the therapy effi-
cacy to a value η0 instantaneously at random Poissonian
times with rate r. Such therapy ”resetting” events can
be due to the introduction of a new dose of drug, the
discovery of more effective variants of the therapy, etc.
See Fig. 1 for an illustration of the model and a sample
stochastic trajectory of the therapy efficacy.
The evolution of the model can be described by the
Fokker-Planck equation with source terms
∂tP + ∂η(vP −D∂ηP ) = −rP + rδ(η − η0), (1)
where P ≡ P (η, t|η0, 0) is the conditional probability
density that the therapy is at η at time t given that
its initial value (at which it is reset at rate r) was η0.
The dynamics is complemented by a absorbing boundary
condition at η = 0, limη→0+ P (η, t) = 0 and a zero-flux
reflecting boundary condition at η = 1, J(1, t) = 0 where
J(η, t) = vP (η, t)−D∂ηP (η, t) is the probability current.
In the following, we derive analytical expressions for
the finite-time survival probability and the mean survival
time. We denote by survival time the first-passage time
of the therapy efficacy to reach the absorbing boundary
η = 0. To this aim, we first make use of a relation be-
tween the finite-time survival probability with resetting
Sr(η0, t) and the survival probability without resetting
S0(η0, t) [20]
Sr(η0, t) = e
−rtS0(η0, t)+r
∫ t
0
dτe−rτS0(η0, τ)Sr(η0, t−τ).
(2)
From Eq. (2) we show that the Laplace transform of
the first passage probability with resetting S˜r(η0, s) and
without resetting S˜0(η0, s) are related through the iden-
tity (see Supplemental Material)
S˜r(η0, s) =
(r + s)S˜0(η0, s+ r)
s+ rS˜0(η0, s+ r)
. (3)
We show that the Laplace transform of the first passage
survival probability without resetting is given by
S˜0(η0, s) = e
− η0v2D 2Dω cosh[ω(η0 − 1)] + v sinh[ω(η0 − 1)]
2Dω coshω − v sinhω
(4)
where ω =
√
v2 + 4Ds/2D. Substituting
Eq. (4) in Eq. (2) and using the relation
〈τr〉 = − lims→0 ∂S˜r(η0, s)/∂s we obtain the follow-
ing analytical expression for the mean first-passage time
〈τr〉 = φ(Pe,Ω, η0)
r
{
Pe sinh
[
Ω
(
η0 − 1
)]
+ Ω cosh
[
Ω
(
η0 − 1
)]}2 ,
(5)
where the non-trivial function φ(Pe,Ω, η0) =
Pe2{ePeη0 cosh[Ω(η0 − 2)] − cosh[2Ω(η0 − 1)]} +
PeΩ {ePeη0 sinh[Ω(η0 − 2)] − sinh[2Ω(η0 − 1)]} +
ePe η0 cosh[Ωη0]−cosh[2Ω(η0−1)]+ePe η0 cosh[Ω(η0−2)]−
1 depends on the model parameters through the dimen-
sionless quantities Pe = v/2D, Ω =
√
v2 + 4Dr/2D,
and ξ = r/2D.
Figure 2 shows an excellent agreement between Eq. (5)
and numerical Langevin-dynamics simulations of the
model, for different parameter values. For positive val-
ues of v, the mean survival time decreases monotonously
with the therapy resetting rate, hence it is beneficial to
switch slowly among beneficial therapies (i.e. keeping r
small) in order to maximize the survival time. For small
and even negative values of the efficacy drift, the mean
first-passage time is non monotonous; the minimum aver-
age survival time takes place for intermediate values of r.
For therapies with large negative bias v < 0, a case that
is is relevant in the context of viral evolution, 〈τr〉 in-
creases monotonically with r, i.e. the maximum average
survival is achieved switching the therapies as frequent
as possible.
In a real-world scenario, practitioners have to deal with
limited resources such as a finite number of therapies dur-
ing the life of a patient. Within this scenario, it is im-
portant to know what is the optimal resetting rate that
achieves a desired value of the mean survival time of the
patient. To study this problem, we evaluate in Fig. 3
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FIG. 2. Mean survival time for a therapy to become com-
pletely inefficient, as a function of the therapy resetting rate:
numerical simulations (symbols) and analytical results (lines)
given by Eq. (5). The data corresponds to parameter values
diffusion D = 1.5, initial efficacy η0 = 1/2 and different val-
ues of drift v: v = 2 (), v = 1 () v = 0 (H), v = −1
(N), and v = −2 (•). For all parameter values, the sim-
ulations were done using Euler’s numerical integration with
parameters: 105 number of simulations, each with time step
∆t = 10−5 and total simulation time tsim = 106.
the resetting rates rmin and rmax for which the mean
survival time attains respectively its minimum and max-
imum value, within a finite range of resetting rate. We
find that rmin = 0 for rapidly evolving virus (v large and
negative), whereas rmin increases monotonously with v
for larger values. Notably rmin presents a non-analyic
behaviour at a critical value of v, and hence of the Peclet
number, as reported by recent work on drift-diffusion pro-
cesses with one absorbing boundary [26]. On the other
hand, our results show that the ”optimal” resetting rate
rmax achieving the maximum mean survival time displays
a dependency with the therapy drift that has reminis-
cences of a first-order phase transition; it exhibits a sud-
den jump from the maximum allowed resetting rate (for
rapidly evolving virus) to zero. Such transition occurs at
a critical value of v that depends on the fluctuations D
of the therapy efficacy; it can take place at biologically
relevant values (v negative) when D is large enough.
We now consider a stochastic mean-field population-
dynamics model describing a multicellular organism con-
taining healthy H, latent L, and productively infective
I cells by a chronic viral disease such as HIV-1. The
state of the system is described by its time-dependent
numbers H, I and L, whose dynamics is driven by the
stochastic-resetting therapy efficacy η. We remark that
we include in the model a population of latent cells to ac-
count for a chronic infection, inspired in previous mathe-
matical models of HIV-1 [4]. The dynamics of the model
is given by three coupled ordinary differential equations
[Eqs. (6-8) below] driven by an autonomous stochastic
● ● ● ● ● ●
● ●
● ● ●
▲ ▲ ▲ ▲ ▲
▲ ▲
▲
▲ ▲ ▲
■ ■ ■ ■
■
■
■
■
■ ■ ■
-4 -2 0 2 4
0
5
10
15
v
r
m
in
● ● ● ● ● ●
● ● ● ● ●
▲ ▲ ▲ ▲ ▲ ▲
▲ ▲ ▲ ▲ ▲
■ ■ ■ ■ ■
■ ■ ■ ■ ■ ■
-4 -2 0 2 4
0
5
10
15
v
r
m
ax
FIG. 3. Comparison between simulations (symbols) and the-
oretical results (lines) of optimal resetting rates as a function
of the therapy efficacy drift: rmin (top) and rmax (bottom) de-
note the value of the resetting rate at which the mean survival
time attains its minimum and maximum values, respectively.
The different curves and symbols are obtained by imposing a
maximum allowed resetting rate of 15, for different values of v
and D = 0.5 (•, red line), D = 1 (N, green line) and D = 1.5
(, purple line). The rest of the simulation parameters are
set to the same values as in Fig. 2.
differential equation [Eq. (9) below]:
dH
dt
= α− λHH − (1− η)βHI (6)
dL
dt
= (1− η)βHI + pL
(
1− L
K
)
− aLL− λLL (7)
dI
dt
= (1− )(1− η)βHI + aLL− λII (8)
dη = (1− χ)(vdt+
√
2DdW ) + χ(η0 − η). (9)
Here, α denotes the rate of recruitment of new healthy
cells, λH is the death rate of healthy cells, β is the in-
fection rate,  is the probability of an infection resulting
into a latent cell, p is the proliferation rate of latent in-
fected cells, K is the carrying capacity which introduces
a logistic growth, aL the activation rate of latent cells,
λL death rate of latent cells, and λI the death rate of in-
fected cells. Note that the infection rate β is multiplied
by the instantaneous probability (1−η) of the infection to
occur. Finally, χ is a binary variable which equals to one
(zero) when a reset occurs (does not occur) with proba-
bility rdt (1−rdt), and W is the Wiener process. Hence,
Eq. (9) complemented with mixed absorbing boundary
conditions describes the previously introduced therapy
efficacy stochastic model. Further details of the model
can be found in the Supplemental Material.
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FIG. 4. Numerical simulations of the viral evolution
population-dynamics model given by Eqs. (6-9) in the ab-
sence (top) and in the presence (bottom) of therapy re-
setting: fraction of healthy cells with respect to the ini-
tial value H/H0 (green line) and therapy efficacy (black
line) as a function of time. The inset in the top panel
shows the average number of healthy cells as a function of
the therapy efficacy in the absence of resetting, and the
red dashed line in the bottom panel illustrates the time at
which the antiviral therapy efficacy is restored to its initial
value. Parameters of the simulations: v = −3 × 10−4days−1
and D = 10−5 days−1, α = 6000 days−1 ml−1, λH =
0.01 days−1, β = 5 × 10−6ml days−1,  = 0.01, p =
0.2 days−1, aL = 0.1 days−1, λL = 0.01 days−1, λI =
1 days−1, K = 100 cells ml−1, with r = 0 (top) and r =
(1/3)years−1 (bottom), with initial condition η0 = 0.8, H0 =
6 × 105 cells ml−1, L0 = 1 cells ml−1, I0 = 0 cells ml−1, and
step size ∆t = 1days. The inset (up) shows the value of H at
the non-trivial fixed point of the system Eqs. (6-8) for a fixed
value of η.
Next, we illustrate the model with numerical simula-
tions showing the impact of the therapy efficacy in the
number of healthy cells of a patient. For this purpose we
numerically integrate Eqs. (6-9). In this case, we only
consider therapies with v < 0 because mutations bene-
ficial to the virus are dominant in its evolution. When
changes in therapy are not allowed we observe a drift in
η through the absorbing barrier, followed by the healthy
cells (Fig. 4, top). Under stochastic changes in the ther-
apy η still drifts through the absorbing state barrier, how-
ever, after the stochastic reset, we often observe a period
in which the healthy cells recover, delaying the absorp-
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FIG. 5. Mean survival times (in years) as a function of the
therapy efficacy drift v and diffusion D. (A,C) Analytical
value of the mean first-passage time for the therapy efficacy
η to reach the absorbing boundary η = 0, given by Eq. (5).
(B,D) Numerical value of the mean time elapsed until the
fraction of healthy cells falls below 1/2 its initial value (B,D).
The color maps show the values obtained for resetting rates
r = 0 (A,B) and r = (1/3)years−1 (C,D). In (B,D) the values
of the simulation parameters were set to the same values as in
Fig. 4 except the time step ∆t = 0.01days, and the averages
are done over 2000 numerical simulations of Eqs. (6-9).
tion time of η (Fig. 4, bottom). We remark that, when
η reaches the absorbing boundary at zero, the cell pop-
ulation still evolves, towards its fixed point. Note that,
unlike in our first model, we allow here for resets from
η = 0 to η0 because even in the absence of therapy the
patient can survive until their therapy changes. This mo-
tivates us to study first-passage times in the context of
healthy cells. In doing so, we define the patient survival
time as the time elapsed until H ≤ α/(2λH), which cor-
responds to the time until it falls below half of the fixed
point in the absence of infection.
We now determine the impact of changes in the ther-
apy in a region of parameters for v and D. Figure 5
shows the mean survival time (left panels) and the mean
patient survival time (right panels) as a function of v
and D obtained from analytical and numerical calcula-
tions. For the parameter values studied here, resetting
therapies increases both the mean survival time and the
mean patient survival time. Their qualitative behaviour
is similar: when the drug resistance develops slowly (v
negative but small) the survival time and the patient
survival time are large, and vice versa. The larger the
resistance fluctuations D, the lower the survival times,
however this dependency is weaker than for v. Notably,
5when executing therapy resets at a rate of (1/3)years−1,
the mean patient survival time can exceed 20 years for
small values of v and D (Fig. 5D).
We have introduced a multi-scale stochastic model
linking drug resistance development described by a one-
dimensional stochastic resetting process with cell pop-
ulation dynamics. We have found that the number of
healthy cells in a chronic disease such as HIV-1 display
negative correlation with the drug resistance. Our ana-
lytical and numerical results quantify the beneficial as-
pects of therapy changes at random Poissonian times for
the mean survival time of a patient as a function of the vi-
ral evolution parameters. We have derived an analytical
expression for the mean survival time of the stochastic-
resetting therapy efficacy as a function of its drift and dif-
fusivity. This expression can be used to estimate patient
survival times in some limits. It will be interesting to ex-
tend our work to e.g. compare different therapy resetting
protocols under time constraints, account for drug resis-
tance development which depends on the instantaneous
viral load, account for multiple therapies [35], etc. We ex-
pect potential applications of our work to determine the
epidemiological impact of drug resistance development,
using models where the immunity to certain drugs can
be transported between individuals.
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6SUPPLEMENTAL MATERIAL
S1. Analytical expression for the mean survival time
In this section we provide additional details about the derivation of Eq. (5) in the Main Text for the mean absorption
time for the one-dimensional stochastic-resetting process that we use to describe the therapy efficacy. The derivation
proceeds as follows: First, we derive an analytical expression for the survival probability in the absence of resetting
r = 0. Next, we use a known relation to derive the Laplace transform of survival probability with resetting from the
survival probability without resetting. Third, we derive the mean survival time from the Laplace transform of the
survival probability with resetting.
First passage without resetting
We first consider for the ease of analytical calculations the case r = 0 in which the therapy efficacy is a drift diffusion
process. We denote by P (η, t) the conditional probability density that the efficacy of the therapy is η at time t, given
that its initial value at time t = 0 was η0. It obeys the Fokker-Planck equation that results from taking r = 0 in
Eq. (1) in the Main Text
∂P (η, t)
∂t
+
∂J(η, t)
∂η
= 0, (S10)
where J(η, t) is the probability current defined in this case as
J(η, t) ≡ vP (η, t)−D∂P (η, t)
∂η
. (S11)
Equations (S10) and (S11) are complemented with the initial and boundary conditions of the process
P (η, t = 0) = δ(η − η0), (S12)
lim
η→0+
P (η, t) = 0, (S13)
J(η = 1, t) = 0. (S14)
Here, Eq. (S12) accounts for the initial condition η(0) = η0, Eq. (S13) for the absorbing boundary at η = 0, and
Eq. (S14) for the reflecting boundary condition at η = 1. Taking the Laplace transform on Eq. (S10), we get
sP(η, s)− P (η, t = 0) + vP ′(η, s)−DP ′′(η, s) = 0, (S15)
where the prime denotes derivative with respect to η and we have introduced the notation
P(η, s) ≡
∫ ∞
0
e−stP (η, t) dt, (S16)
for the Laplace transform of the propagator. Applying the initial condition (S12) into Eq. (S15), we obtain
sP(η, s)− δ(η − η0) + vP ′(η, s)−DP ′′(η, s) = 0. (S17)
We now concentrate our efforts in obtaining an analytical solution to Eq. (S17). First we express P(η, s) as a
piecewise continuous function:
P(η, s) =
{ P<(η, s) when η < η0
P>(η, s) when η > η0,
(S18)
for η 6= η0. Both P< and P> obey Eq. (S17) in η < η0 and η > η0 respectively, i.e.
DP ′′<(η, s)− vP ′<(η, s)− sP<(η, s) = 0, (S19)
DP ′′<(η, s)− vP ′<(η, s)− sP<(η, s) = 0. (S20)
7The solutions of Eqs. (S19-S20) are given by sums of exponential functions
P<(η, s) = a+eα+η + a−eα−η, (S21)
P>(η, s) = b+eα+η + b−eα−η. (S22)
Plugging in Eq. (S21) in (S19) and Eq. (S22) in (S20) yields the second order equation
Dα2± − vα± + s = 0, (S23)
whose solutions are given by
α± =
v
2D
± w, (S24)
where
w ≡
√
v2 + 4Ds
2D
. (S25)
The parameters a+, a−, b+, and b− can be determined using the boundary conditions. Applying the absorbing
boundary condition (S13) into Eq. (S21) we get a+ + a− = 0, hence defining a ≡ a+, we find that P< has the form
P<(η, s) = a
[
eα+η − eα−η
]
. (S26)
Next, we use the reflecting boundary condition (S14) in (S22) which implies vP>(η = 1, s) = DP ′>(η = 1, s). This
results in the following relation v
[
b+e
α+ + b−eα−
]
= D
[
α+b+e
α+ + α−b−eα−
]
, or equivalently (v − Dα+)eα+b+ =
(Dα− − v)eα−b− ≡ b. Thus we get
P>(η, s) = b
[
eα+(η−1)
v −Dα+ −
eα−(η−1)
v −Dα−
]
. (S27)
The continuity condition of P(η, s) at η = η0 in Eqs. (S26-S27) implies that
b
[
eα+(η0−1)
v −Dα+ −
eα−(η0−1)
v −Dα−
]
= a [eα+η0 − eα−η0 ] ≡ c (S28)
therefore
P<(η, s) = c
[
eα+η − eα−η
eα+η0 − eα−η0
]
, (S29)
P>(η, s) = c

eα+(η−1)
v −Dα+ −
eα−(η−1)
v −Dα−
eα+(η0−1)
v −Dα+ −
eα−(η0−1)
v −Dα−
 . (S30)
To solve for c, we solve the differential equation (S17) at η = η0,
DP ′′(η, s) = vP ′(η, s) + sP(η, s)− δ(η − η0). (S31)
Take the integral both sides with respect to η from η0 −  to η0 +  and then the limit of  to 0 we obtain
D
[
P ′>(η0, s)− P ′<(η0, s)
]
= v
[
P>(η0, s)− P<(η0, s)
]
− 1 (S32)
The first term at the right-hand side vanishes due to the continuity condition, therefore
P ′>(η0, s)− P ′<(η0, s) = −
1
D
. (S33)
8Using Eqs. (S29) and (S30) in (S33) and solving for c we get, after some cumbersome simplifications,
c =
2
(
√
v2 + 4Ds cosh
[√
v2 + 4Ds(η0 − 1)
2D
]
+ v sinh
[√
v2 + 4Ds(η0 − 1)
2D
])
sinh
[√
v2 + 4Dsη0
2D
]
(v2 + 4Ds) cosh
[√
v2 + 4Ds
2D
]
− v√v2 + 4Ds sinh
[√
v2 + 4Ds
2D
] . (S34)
The Laplace transform of the first-passage (survival) time probability at η = 0 without resetting is given by [36]
F0(s) = D ∂
∂η
P<(η, s)
∣∣∣∣
η=0
− vP<(η, s)
∣∣∣∣
η=0
, (S35)
where the second term at the right-hand side vanishes because of the absorbing boundary condition. Note that here
we have introduced the subscript 0 to emphasize that this first-passage statistic refers to the case r = 0. Since c does
not depend on η, Eq. (S35) together with Eq. (S29) imply that
F0(s) = cD α+ − α−
eα+η0 − eα−η0 . (S36)
Substituing the values of α+ and α− [Eq. (S24)] and C [Eq. (S34)] in Eq. (S36) we arrive at the analytical expression
for the Laplace transform of the first-passage-time probability for the drift-diffusion process with mixed boundary
conditions:
F0(s) =
√
v2 + 4Ds
(
√
v2 + 4Ds cosh
[√
v2 + 4Ds(η0 − 1)
2D
]
+ v sinh
[√
v2 + 4Ds(η0 − 1)
2D
])
exp
[η0v
2D
](
(v2 + 4Ds) cosh
[√
v2 + 4Ds
2D
]
− v√v2 + 4Ds sinh
[√
v2 + 4Ds
2D
]) . (S37)
From Eq. (S37) we can also derive an analytical expression for the Laplace transform of the survival probability,
which is defined as follows
S0(s) ≡
∫ 1
0+
dηP(η, s) (S38)
=
∫ η0
0+
P<(η, s) dη +
∫ 1
η0
P>(η, s) dη, (S39)
where in the second line we have used Eq. (S18). We now recall the relation (valid for any η0 > 0) between the survival
probability and the first passage probability F0(t) = −∂tS0(t) which takes the form F0(s) = − [sS0(s)− S0(t = 0)]
upon taking the Laplace transform, or equivalently
F0(s) = 1− sS0(s). (S40)
Here we haved used the fact that at time t = 0, the process has not been absorbed by the absorbing boundary η = 0,
i.e. η0 > 0.
First passage with resetting
Following [20, 37], the survival probability with resetting (denoted here with subscript r) obeys a renewal equation
together with the survival probability without resetting
Sr(t) = e
−rtS0(t) + r
∫ t
0
dτe−rτS0(τ)Sr(t− τ) (S41)
Taking the Laplace transform on both sides of Eq. (S41), we get Sr(s) = S0(s + r) + rS0(s + r)Sr(s), which solving
for Sr(s) yields
Sr(s) = S0(s+ r)
1− rS0(s+ r) . (S42)
9Therefore, the Laplace transform of the first-passage-time probability with resetting can be expressed in terms of the
Laplace transform of the survival probability without resetting as follows
Fr(s) = 1− sS0(s+ r)
1− rS0(s+ r) . (S43)
Shifting the relation (S40) from s to s+ r, i.e. using S0(s+ r) = (1−F0(s+ r)) /(s+ r) in Eq. (S43) we obtain after
some simplifications
Fr(s) =
(
r + s
)
F0(s+ r)
s+ rF0(s+ r) (S44)
After some algebra, in using Eq. (S37) in (S44) and the relation 〈τr〉 = − lims→0 ∂sFr(s) we derive Eq. (5) in the
Main Text for the mean first-passage time, copied here for convenience
〈
τr
〉
=
Pe2
 exp
[
Pe η0
]
cosh
[
Ω
(
η0 − 2
)]
− cosh
[
2Ω
(
η0 − 1
)]

+Pe Ω
 exp
[
Pe η0
]
sinh
[
Ω
(
η0 − 2
)]
− sinh
[
2Ω
(
η0 − 1
)]

− ξ

1
+ cosh
[
2Ω
(
η0 − 1
)]
− exp
[
Pe η0
]
cosh
[
Ωη0
]
− exp
[
Pe η0
]
cosh
[
Ω
(
η0 − 2
)]

r
{
Pe sinh
[
Ω
(
η0 − 1
)]
+ Ω cosh
[
Ω
(
η0 − 1
)]}2 (S45)
where we have introduced the variables
Ω =
√
v2 + 4Dr
2D
; Pe =
v
2D
; ξ =
r
2D
. (S46)
S2. Details of the biophysical model
Our biological model [Eqs. (6-9) in the Main Text] is an adaptation of that reported in Ref. [4] and describes the
evolution of three different cell populations in blood: healthy cells H which are susceptible to be infected, infected
cells L which are in a latent state, and productively infected cells I which can infect healthy cells. The dynamics is
described by the reactions described below, where the chronic feature is modelled by adding a latent population with
a logistic growth. Such dynamics have been hypothesized in [38] and used to model HIV-1 dynamics in [4, 5].
• Recruitment of a new healthy cell by the organism at a rate a: ∅ → H.
• Death of a healthy at a rate λH : H → ∅.
• A healthy cell being infected, which we assume it is proportional to the number of infected cells, I, and inversely
proportional to the efficacy of the therapy η, at a rate β. With probability  the resulting cell will be a latent
cell: H → L, and with probability 1−  the resulting cell will be a productively infected cell: H → I.
• Proliferation of a latent cell with rate p: L→ L+ L.
• Death of latent cells by competition for resources, with rate pK : L + L → ∅. This is an artificial reaction to
mimic the logistic growth, see [5] for details in HIV-1 modeling.
• Activation of a latent cell resulting into a productively infected cell at rate aL: L→ I.
• Death of a latent cell at rate λL: L→ ∅.
• Death of a productively infected cell at rate λI : I → ∅.
A mean-field formulation of the dynamics of the system leads to the ordinary differential equations (6-8) in the Main
Text.
